Featured

  • Aseptic Processing | Facilities | Fill/Finish | Parenterals
    The Future of Pharmaceutical Manufacturing

    The Future of Pharmaceutical Manufacturing

    Innovative multi-product facility and equipment design.
    Steve Nole, VP of Operations, Grand River Aseptic Manufacturing 01.27.21
  • Solid Dosage/Creams/Ointments
    Recent Advances in Solid Dispersion Technologies

    Recent Advances in Solid Dispersion Technologies

    Improving the bioavailability and therapeutic efficiency of poorly soluble drugs.
    José L. Toro, Directory, Lachman Consultants 01.27.21
  • Biologics, Proteins, Vaccines
    Vaccines 2021

    Vaccines 2021

    Looking at the behavioral economics of vaccinations.
    Ben Locwin, Contributing Editor 01.27.21
  • The Art and Science of Recruitment

    The Art and Science of Recruitment

    Chapter Four: Interview day and the importance of the hiring manager.
    David G. Jensen, Contributing Editor 01.27.21
  • Solid Dosage/Creams/Ointments
    High Drug Loading Amorphous Solid Dispersions

    High Drug Loading Amorphous Solid Dispersions

    A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
    Deanna Mudie and Aaron Stewart, Lonza 01.27.21
  • Parenterals
    Parenteral Drug Delivery Trends

    Parenteral Drug Delivery Trends

    A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
    Kristin Brooks, Managing Editor, Contract Pharma 01.27.21
  • Selecting the Right Outsourcing Model for Emerging Biotech

    Selecting the Right Outsourcing Model for Emerging Biotech

    Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
    Timothy King and Elisha Talley-Roithner, PPD 01.27.21
  • Drug Delivery
    Inhaled Drug Delivery Technology

    Inhaled Drug Delivery Technology

    The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
    Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21
  • Biologics, Proteins, Vaccines
    The Future of Biologics: Accelerating Production, Reducing Costs

    The Future of Biologics: Accelerating Production, Reducing Costs

    Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
    Mark Emalfarb, Dyadic 01.27.21
  • Analytical Services | Information Technology | Laboratory Testing
    Business Intelligence For (and From) the Lab

    Business Intelligence For (and From) the Lab

    How a digital ecosystem can harness the most data-rich environment in the CDMO.
    Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21
  • Communicating Your Contracting Priorities to Your Drug Company Customers

    Communicating Your Contracting Priorities to Your Drug Company Customers

    A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
    Stephen Sayre, Dykema 01.27.21
  • COVID-19 Impact Report

    COVID-19 Impact Report

    Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
    Tim Wright, Editor, Contract Pharma 01.27.21
  • Biologics, Proteins, Vaccines | Regulatory Affairs
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
    Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21
  • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
    Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies

    Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies

    Lilly expands BLAZE-4 trial to evaluate bamlanivimab with VIR-7831, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein.
    Kristin Brooks 01.27.21
  • Breaking News | Collaborations & Alliances | Industry News | Injectables
    Novartis Invests in Credence MedSystems

    Novartis Invests in Credence MedSystems

    Supporting ramp-up of manufacturing capacity for innovative injectable drug delivery systems.
    Tim Wright, Editor, Contract Pharma 01.27.21